DJIA 18,081.61 -81.38 -0.45%
NASDAQ 5,090.26 -16.33 -0.32%
S&P 500 2,115.21 -8.27 -0.39%
market minute promo

Synageva BioPharma (NASDAQ: GEVA)

214.61 -1.16 (-0.54%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

GEVA $214.61 -0.54%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $215.19
Previous Close $215.77
Daily Range $213.45 - $215.80
52-Week Range $60.19 - $218.80
Market Cap $8.0B
P/E Ratio -33.93
Dividend (Yield) $0.00 (0.0%)
Volume 136,886
Average Daily Volume 1,279,880
Current FY EPS -$7.36




Drug Makers

Synageva BioPharma (GEVA) Description

A biopharmaceutical company primarily engaged in the discovery, development and commercialization of a new class of antiviral drug treatments called fusion inhibitors. Website:

News & Commentary

Investors Just Doubled Their Money on This Stock

Alexion is paying $8.4 billion to buy Synageva, a company without any sales, so in today's episode we're digging into this deal to see what it may mean to biotech investors.

Synageva BioPharma Files for Kanuma's Approval in Japan - Analyst Blog

Synageva BioPharma Submits Kanuma (Sebelipase Alfa) Application For LAL Deficiency In Japan

4 Big Biotech Companies to Sell Now

Oppenheimer Downgrades Dyax

Will Suitors Line Up to Buy These Biotech Stocks Next?

BioMarin Therapeutic Inc. and Amicus Therapeutics, Inc. are working on ultra-rare disease drugs that could attract an acquirer.

Alexion Acquiring Synageva For $8.4 Billion

Alexion to Buy Synageva for $8.4B: Alexion Down, Synageva Up - Analyst Blog

Morgan Stanley: Market's Reaction To Linger For Alexion Pharmaceuticals

Here's What Canaccord Learned After Spending A Day With Synageva's Management

See More GEVA News...

GEVA's Top Competitors

GEVA $214.61 (-0.54%)
Current stock: GEVA
AMGN $157.87 (-1.60%)
Current stock: AMGN
GILD $113.16 (0.62%)
Current stock: GILD
BIIB $400.55 (-0.59%)
Current stock: BIIB